Enzyme Toothpaste Tablet OEM: How To Approve Clean-Feel And Anti-Redeposition Candidates Without Raising Abrasivity

TAKEAWAYS

• 1. Treat five inputs as separately specified candidates: papain, lysozyme, sodium pyrophosphate, sodium tripolyphosphate, and sodium phytate need their own identity, grade, supplier lot, formula basis, and compatibility review.

• 2. Use four matched samples rather than one “enhanced” prototype: compare a controlled base, an enzyme route, an anti-redeposition route, and a combined route while holding the abrasive, tablet, flavor, process, and pack as constant as practical.

• 3. Require final-formula abrasion evidence: relative dentin abrasivity (RDA) and relative enamel abrasivity (REA) address a different approval question from clean feel, a raw-material CoA, or a supplier’s ingredient story.[3]

• 4. Do not transfer one 8-week toothpaste study into a tablet formula: the adult study tested one silica/phytate/pyrophosphate toothpaste mixture, not a compressed tablet, and did not identify a separate effect for sodium phytate or sodium pyrophosphate.[1]

• 5. Approve one version-controlled dossier before bulk production: formula, material lots, activity method/results where relevant, abrasion decision, sensory record, tablet/pack results, and Canada classification/label review should travel together.

What Does an Enzyme Toothpaste Tablet OEM Brief Approve?

It approves a finished, compressed-tablet development route before artwork or bulk production. The written brief should name the intended market, use and claim boundary, candidate materials, final-pack concept, clean-feel decision criteria, and the evidence owner for each gate.

Papain is a protease and lysozyme is a distinct enzyme protein. Sodium pyrophosphate is a diphosphate and sodium tripolyphosphate is a triphosphate; both are condensed inorganic phosphates. Sodium phytate is the sodium salt of myo-inositol hexakisphosphate, an inositol-based organophosphate, not a condensed phosphate. Treat all five as separately specified candidates, not formula substitutes.

For format context, visit Qiaoerna’s toothpaste tablet OEM/ODM range. This article addresses the approval system after a brand has selected the tablet format.

Why Is “Clean Feel” Not One Ingredient Result?

Clean feel is a sensory outcome, not a stand-alone laboratory or ingredient result. Tablet breakup, abrasive morphology, foam, flavor, cooling, residue, brush use, and the chosen comparison condition can all change the experience. Keep four decisions separate:

An 8-week study reported lower extrinsic-stain scores for a toothpaste containing 10% high-cleaning silica, 0.5% sodium phytate, and 0.5% sodium pyrophosphate versus a negative control. The authors could not isolate each ingredient’s contribution.[1] It is useful context for an evidence plan, not a percentage recommendation, compressed-tablet result, or consumer claim.

Problem #1 — An Enzyme Is Added, but Finished-Tablet Activity Is Unknown

An enzyme route is not approved until its activity method is defined for the finished tablet. A raw-material CoA supports incoming-material qualification; it cannot establish activity after blending, compression, packaging, and storage.

In topical emulsions, papain activity varied with formulation and storage temperature.[2] That is not a tablet result; it supports using a formula-specific finished-tablet activity and stability method. Record material identity, source, activity unit, lot, formula version, process conditions, final-tablet sample preparation, reporting unit, storage checkpoints, and final-pack configuration.

Problem for brands: an enzyme appears on the ingredient list, but no one can state what the finished tablet was tested to retain.

OEM response: agree the method, acceptance approach, and change-control trigger before sample approval; retain results beside the approved formula and material lots.

Problem #2 — Candidate Materials Are Treated as Formula Substitutes

Sodium pyrophosphate, sodium tripolyphosphate, and sodium phytate should not be grouped into one “phosphate system.” Their identity, grade, formula basis, method, taste, pH-on-use, moisture response, flavor compatibility, and finished-tablet behavior must be recorded separately.

The published toothpaste study used a multi-ingredient mixture. It does not establish a stand-alone effect, a tablet dose, or a consumer claim for any one candidate.[1] Compare the chosen candidate against a matched control, and keep the product description within the final-product evidence.

Problem for brands: a quotation names an “anti-redeposition system,” but the material identity and finished-tablet evidence are absent.

OEM response: lock the selected candidate and its version-controlled specification before interpreting a sample result.

Problem #3 — a Clean-Feel Request Raises Abrasivity by Default

Do not answer a clean-feel request by automatically increasing abrasive loading. Smoothness, surface-stain screening, and abrasion are separate approval gates. Relative dentin abrasivity (RDA) and relative enamel abrasivity (REA) are common measures, yet a raw abrasive specification cannot replace finished-formula evidence.[3]

For the exact approved formula, decide whether an RDA/REA report is needed; define the test method/laboratory, the version to be tested, the acceptance decision, and the change that would require re-evaluation. Use a separate controlled sensory record for smoothness, grit, foam, residue, bitterness, cooling, and repeat-use acceptance.

For background on raw-material choice, see Qiaoerna’s toothpaste abrasive selection guide.

Problem for brands: a raw abrasive data sheet is treated as evidence for the entire tablet.

OEM response: approve the finished formula’s evidence plan, not a material story.

Problem #4 — Canadian Classification and Label Review Start After Artwork

Canada-specific classification and label review must start before artwork approval, not after it. Health Canada’s Oral Health Products Monograph lists ingredient, route, dosage-form, use, dose, directions, and subpopulation conditions for defined pathways.[4] Before artwork approval, obtain Canada-specific confirmation that the final tablet’s dosage-form classification, formula, proposed claims, directions, and label fit the selected route. Do not infer the route from tablet format alone.

Problem for brands: a tablet design and label are approved before the proposed Canadian route is documented.

OEM response: place classification, formula, directions, claims, and label review in the sample-release dossier before packaging artwork is locked.

How Should Brands Run a Four-Arm OEM Sample Screen?

Compare matched prototypes before choosing a marketing narrative. Keep abrasive grade, tablet size, flavor direction, process conditions, and pack as constant as practical across four arms:

This is a development comparison, not a universal formula, clinical study, or establishment of a final consumer claim.

Which Version-Controlled Gates Should Approve a Canadian Sample?

Use a six-gate dossier before commercial release. The table assigns a decision owner; it does not imply that one supplier performs every test or regulatory service.

For detail on tablet-release controls such as hardness, friability, and disintegration, read Qiaoerna’s compression and batch-release guide.

Send Qiaoerna the target market, proposed claim boundary, candidate materials, final-pack concept, and launch timing to request a four-arm, version-controlled sample-approval brief. Discuss a custom oral-care OEM project.

FAQ: Enzyme Toothpaste Tablet OEM, Sampling, MOQ, and Canada

Can papain and lysozyme be used together in a toothpaste tablet?

Only after identity, source, activity basis, compatibility, sensory effect, and finished-tablet stability are defined. A raw-material list does not establish a finished, market-ready combination.

Are sodium pyrophosphate, sodium tripolyphosphate, and sodium phytate the same ingredient?

No. The first two are different condensed inorganic phosphates; sodium phytate is an inositol-based organophosphate. Request each candidate’s identity, grade, CoA, formula basis, and evidence plan.

Can enzymes replace abrasives in a toothpaste tablet?

Do not assume so. Enzyme activity, physical cleaning, surface-stain screening, foam, and abrasion are separate variables in the final-product brief.

Can a lower-abrasivity tablet still provide a convincing clean feel?

Potentially, but use controlled sensory comparison of the finished formula; do not infer the result from one ingredient or use it instead of abrasion evidence.

Can a compressed toothpaste tablet be assumed to fit a Canadian monograph pathway?

No. Confirm the final dosage-form classification, intended use, ingredient roles, proposed claims, directions, and label through the selected Canadian route before approving artwork or bulk production.

How is enzyme activity checked in a finished toothpaste tablet?

Agree a formula-specific method, sample preparation, reporting unit, acceptance approach, and storage checkpoints for the final formula and pack—not only the incoming raw material.

What is the MOQ and sampling sequence for a custom enzyme toothpaste tablet?

MOQ is set only after the formula route, candidate sourcing, final pack, required testing, and documentation scope are written into the sample brief. A laboratory sample is not a commercial batch.

Which version-controlled records must travel with the approved Canadian sample?

The approved formula/material records, activity results where relevant, abrasion decision, sensory record, tablet/final-pack results, and Canadian classification, label, and claim review should be version-controlled together.

Conclusion

A request for a stronger clean feel without defaulting to a more aggressive abrasive system is a finished-product approval problem. Compare matched samples, distinguish each candidate, and approve one evidence dossier before artwork and bulk production.

References

[1] Liu H, et al. (2021). BMC Oral Health, 21, 16. DOI.

Boundary: one adult toothpaste mixture; no compressed-tablet or separate-ingredient outcome.

[2] Pinto CASO, et al. (2011). Brazilian Journal of Pharmaceutical Sciences. Source.

Boundary: topical-formulation context only.

[3] Stovell AG, et al. (2022). International Dental Journal. Open article.

Boundary: RDA/REA context, not a formula-specific result.

[4] Health Canada. (2026). “Oral Health Products Monograph.” Official source.

Boundary: confirm route from final classification, formula, use, directions, and label.

Author: Xiaoying, Research & Development Lead, Qiaoerna.